MedPacto Signs Third Global Joint Clinical Trial Operation Agreement with US Cancer Institute

[Asia Economy Reporter Cho Hyun-ui] MedPacto announced on the 22nd that it has signed a joint clinical trial operation agreement with the world-renowned cancer research institute, the Fred Hutchinson Cancer Research Center in the United States.

Accordingly, MedPacto will jointly conduct a U.S. clinical trial with Fred Hutchinson, administering a combination of its anticancer drug candidate ‘Bactosertib’ and AstraZeneca’s immuno-oncology drug ‘Imfinzi’ to patients with non-muscle invasive bladder cancer in advanced or recurrent stages.

This clinical trial plans to observe how much the response rate can be improved by combining Bactosertib and Imfinzi in patients who did not respond or only partially responded to existing immuno-oncology drugs.

The clinical administration is scheduled to begin within the first half of this year at Fred Hutchinson and the University of California, San Francisco (UCSF) Medical Center. AstraZeneca will provide the drug costs required for the trial.

A MedPacto official stated, "Since Fred Hutchinson possesses the largest cancer immunotherapy research network in the U.S., we plan to conduct multi-center clinical trials at prominent cancer research institutes and major university hospitals across the United States."

Previously, in December last year, MedPacto received approval from the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical trial plan for combination therapy of Bactosertib targeting bladder cancer. This is the third time MedPacto is conducting joint clinical trials with global pharmaceutical companies.

Kim Sung-jin, CEO of MedPacto, said, "We will do our best to achieve continuous and effective responses in cancer patients."

This content was produced with the assistance of AI translation services.